Key Takeaway
Explore the evidence on tirzepatide for heart disease. Learn about SURMOUNT-MMO, heart failure data, and how this dual GLP-1/GIP agonist may protect cardiovascular health.
Tirzepatide for heart disease is a rapidly evolving area of study, with the ongoing SURMOUNT-MMO cardiovascular outcomes trial expected to deliver definitive results around 2027, while early heart failure data from the SUMMIT trial already show significant symptom improvement and reduced hospitalizations.
How Heart Disease
Cardiovascular disease kills more people globally than any other condition, accounting for roughly 17.9 million deaths per year according to the World Health Organization. Within this broad category, two forms are especially relevant to the conversation about tirzepatide: atherosclerotic cardiovascular disease (ASCVD), which includes heart attacks and strokes caused by plaque in the arteries, and heart failure, where the heart can't pump blood effectively enough to meet the body's needs.
The connection between obesity and heart disease is bidirectional. Obesity promotes atherosclerosis through inflammation, insulin resistance, dyslipidemia, and hypertension. At the same time, excess weight strains the heart muscle itself, leading to structural changes (cardiac remodeling) that can progress to heart failure. A 2018 analysis in the European Heart Journal by Kenchaiah et al. found that for every unit increase in BMI, the risk of heart failure increased by 5 percent in men and 7 percent in women. obesity and heart disease
This dual burden makes therapies that address both weight and cardiovascular health particularly appealing.
What the Research Shows
The SUMMIT Trial: Heart Failure with Preserved Ejection Fraction
The SUMMIT trial, presented at the American Heart Association Scientific Sessions in 2024, studied tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. HFpEF accounts for roughly half of all heart failure cases and has been one of the most treatment-resistant conditions in cardiology. For a complete cost breakdown, see our compare tirzepatide prices.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Tirzepatide reduced the composite of cardiovascular death or worsening heart failure events by 38 percent compared to placebo (HR 0.62, 95% CI 0.48-0.81). Heart failure hospitalizations and urgent visits decreased substantially. Patients also experienced a 7.5-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, indicating clinically meaningful symptom relief.
The magnitude of this benefit was striking. Few therapies have shown this level of efficacy in HFpEF, making tirzepatide potentially the most impactful intervention for this population in over a decade.
SURMOUNT-MMO: The Pending Cardiovascular Outcomes Trial
Eli Lilly initiated SURMOUNT-MMO, a dedicated cardiovascular outcomes trial, enrolling approximately 15,000 adults with overweight or obesity and established cardiovascular disease or multiple cardiovascular risk factors but without diabetes. The primary endpoint is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results are anticipated around 2027.
Until SURMOUNT-MMO reports, we can't definitively say whether tirzepatide reduces heart attacks and strokes in the same way that semaglutide did in the SELECT trial[1]. But the strong metabolic improvements seen in SURMOUNT-1[2] and SURMOUNT-2[3], combined with the SUMMIT heart failure data, provide strong biological plausibility.
Metabolic Markers Relevant to Cardiovascular Protection
Across the SURMOUNT trials, tirzepatide improved virtually every modifiable cardiovascular risk factor. At the 15 mg dose: systolic blood pressure decreased by 7.2 mmHg, triglycerides decreased by 27 percent, high-sensitivity CRP decreased by approximately 35 to 40 percent, and insulin resistance (HOMA-IR) improved by approximately 60 percent. These changes collectively paint a picture of thorough cardiovascular risk reduction.
How Tirzepatide May Help
Tirzepatide's dual GLP-1/GIP receptor agonism provides several potential pathways for cardiovascular protection. tirzepatide mechanism of action
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Inflammation reduction: Chronic inflammation is a driver of both plaque instability and heart failure progression. Tirzepatide's 35 to 40 percent reduction in CRP is comparable to what was seen with canakinumab in the CANTOS trial, which proved that reducing inflammation independently lowers cardiovascular event rates. While the mechanism differs (tirzepatide works through metabolic improvement rather than direct IL-1 beta blockade), the magnitude of CRP reduction suggests a meaningful anti-inflammatory contribution.
Cardiac remodeling: Obesity causes the heart to remodel: the left ventricle thickens, filling pressures rise, and diastolic function deteriorates. Weight loss reverses some of these changes. A cardiac MRI sub-study within the STEP-HFpEF program (using semaglutide, a closely related agent) showed reductions in left ventricular mass and improved diastolic filling. Similar effects are expected with tirzepatide given the even greater weight loss it produces.
Improved endothelial function: Both GLP-1 and GIP receptor activation have been associated with enhanced nitric oxide bioavailability in blood vessels, improving vasodilation and reducing endothelial dysfunction.
Epicardial fat reduction: Epicardial adipose tissue (fat surrounding the heart) is directly inflammatory and contributes to coronary artery disease and heart failure. Weight loss with incretin-based therapies has been shown to substantially reduce epicardial fat volume. A study by Iacobellis et al. demonstrated that GLP-1 agonist therapy reduced epicardial fat thickness by 15 to 20 percent.
Important Safety Information
Tirzepatide (as Mounjaro) is FDA-approved for type 2 diabetes. As Zepbound, it's approved for chronic weight management. It doesn't yet have an FDA-approved cardiovascular indication, though the SUMMIT data may support future applications.
In patients with heart disease, healthcare providers should be alert to several considerations. Dehydration from GI side effects (nausea, vomiting, diarrhea) can be particularly problematic in patients on diuretics, ACE inhibitors, or ARBs, as the combination may impair kidney function.
The 2 to 4 bpm increase in resting heart rate seen with incretin-based therapies hasn't been associated with adverse outcomes in trials, but patients with atrial fibrillation or other arrhythmias should be monitored.
Tirzepatide carries a boxed warning about thyroid C-cell tumors in rodent studies and is contraindicated in patients with medullary thyroid carcinoma or MEN2. tirzepatide safety information
Who Might Benefit
Based on current evidence, tirzepatide may be most valuable for cardiovascular health in these patient groups:
- Adults with HFpEF and obesity, where the SUMMIT trial data provide the strongest evidence
- Patients with multiple cardiovascular risk factors (hypertension, dyslipidemia, insulin resistance) driven by obesity
- Adults with type 2 diabetes and cardiovascular risk, where Mounjaro addresses glucose while potentially protecting the heart
- People with metabolic syndrome who need thorough cardiometabolic risk reduction
For patients with established ASCVD (prior heart attack or stroke) who don't have diabetes, the evidence for cardiovascular event reduction is stronger with semaglutide (based on SELECT) until SURMOUNT-MMO results become available.
How to Talk to Your Doctor
The conversation about tirzepatide and heart disease will depend on your specific cardiovascular condition:
- If you have HFpEF and obesity, reference the SUMMIT trial and its 38 percent reduction in cardiovascular death or worsening heart failure
- If you have multiple risk factors, discuss your overall cardiometabolic burden and whether tirzepatide could address several issues simultaneously
- If you have established ASCVD, acknowledge that SURMOUNT-MMO is still ongoing and discuss whether semaglutide (with its completed SELECT data) might be more appropriate in the interim
- Ask about coordination between your cardiologist and primary care provider or endocrinologist to ensure all aspects of your cardiovascular health are managed coherently
Coordinating cardiac and metabolic care
Frequently Asked Questions
Has tirzepatide been proven to prevent heart attacks?
Not yet definitively. The SURMOUNT-MMO cardiovascular outcomes trial is ongoing and expected to report around 2027. The SUMMIT trial showed reduced heart failure events, but a dedicated ASCVD outcomes trial is needed to confirm whether tirzepatide prevents heart attacks and strokes.
How does tirzepatide compare to semaglutide for heart disease?
Semaglutide currently has stronger evidence for ASCVD event reduction (via SELECT). Tirzepatide has stronger early data for heart failure with preserved ejection fraction (via SUMMIT). Both produce substantial weight loss and metabolic improvement. The choice between them should be guided by your specific cardiovascular condition and overall clinical profile.
Is tirzepatide safe for people who have had a heart attack?
Tirzepatide has been studied in patients with cardiovascular risk factors and appears generally well-tolerated. But patients recovering from a recent heart attack should discuss timing and safety with their cardiologist, paying particular attention to hydration status and the potential for GI side effects to interfere with medication adherence and nutrition.
Medical References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
Taking the Next Step
Tirzepatide's cardiovascular story is still being written, but the early chapters are promising. The SUMMIT trial marks a potential breakthrough for HFpEF, and SURMOUNT-MMO may establish tirzepatide alongside semaglutide as a proven cardiovascular protector.
At FormBlends, we follow the science as it unfolds. Stay informed through our resources, and bring your questions to your healthcare team. GLP-1 medications overview